Plain-English translation of NCT07403097 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called cells Injection, which is a type of cell therapy designed to treat severe lupus that hasn't responded to standard medications. The treatment works by taking your own immune cells, modifying them in the lab to target disease-causing cells, and putting them back into your body. This is a small early-stage study with 18 participants to see if the treatment is safe and effective.
Current lupus treatments like steroids and immunosuppressants can control symptoms but don't cure the disease, meaning patients must take medication for life and risk relapse if they stop. This new treatment aims to eliminate the disease-causing cells more completely, potentially offering a long-term solution rather than lifelong medication.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors will collect some of your blood cells through a process called leukapheresis (similar to donating plasma). These cells will be modified in the laboratory over about 10 minutes and then returned to your body as an infusion. You will then be monitored closely during multiple clinic visits to check for side effects and to see how well the treatment works. The study will track your lupus symptoms and overall health for an extended period after treatment.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Chongqing Precision Biotech Co., Ltd
Enrollment target
~18 participants
Started
February 2026
Primary completion
April 2028
Age range
5 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiaodong Zhao
Chongqing Precision Biotech Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.